Literature DB >> 32721952

Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective.

Amir Shabaka1, Ana Tato Ribera1, Gema Fernández-Juárez2.   

Abstract

Focal segmental glomerulosclerosis (FSGS) is a histological pattern of glomerular injury, rather than a single disease, that is caused by diverse clinicopathological entities with different mechanisms of injury with the podocyte as the principal target of lesion, leading to the characteristic sclerotic lesions in parts (i.e., focal) of some (i.e., segmental) glomeruli. The lesion of FSGS has shown an increasing prevalence over the past few decades and is considered the most common glomerular cause leading to ESKD. Primary FSGS, which usually presents with nephrotic syndrome, is thought to be caused by circulating permeability factors that have a main role in podocyte foot process effacement. Secondary forms of FSGS include maladaptive FSGS secondary to glomerular hyperfiltration such as in obesity or in cases of loss in nephron mass, virus-associated FSGS, and drug-associated FSGS that can result in direct podocyte injury. Genetic FSGS is increasingly been recognized and a careful evaluation of patients with atypical primary or secondary FSGS should be performed to exclude genetic causes. Unlike primary FSGS, secondary and genetic forms of FSGS do not respond to immunosuppression and tend not to recur after kidney transplantation. Distinguishing primary FSGS from secondary and genetic causes has a prognostic significance and is crucial for an appropriate management. In this review, we examine the pathogenesis, clinical approach to distinguish between the different causes, and current recommendations in the management of FSGS.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Diagnosis; Focal segmental glomerulosclerosis; Treatment

Year:  2020        PMID: 32721952     DOI: 10.1159/000508099

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  14 in total

1.  Benefit of B7-1 staining and abatacept for treatment-resistant post-transplant focal segmental glomerulosclerosis in a predominantly pediatric cohort: time for a reappraisal.

Authors:  George W Burke; Jayanthi Chandar; Junichiro Sageshima; Mariella Ortigosa-Goggins; Pooja Amarapurkar; Alla Mitrofanova; Marissa J Defreitas; Chryso P Katsoufis; Wacharee Seeherunvong; Alexandra Centeno; Javier Pagan; Lumen A Mendez-Castaner; Adela D Mattiazzi; Warren L Kupin; Giselle Guerra; Linda J Chen; Mahmoud Morsi; Jose M G Figueiro; Rodrigo Vianna; Carolyn L Abitbol; David Roth; Alessia Fornoni; Phillip Ruiz; Gaetano Ciancio; Eduardo H Garin
Journal:  Pediatr Nephrol       Date:  2022-05-04       Impact factor: 3.714

2.  STAT-3 signaling role in an experimental model of nephropathy induced by doxorubicin.

Authors:  Thabata Caroline de Oliveira Santos; Gabriel Pereira; Anna Gabrielle Gomes Coutinho; Halison Pereira Dos Santos Silva; Marcelo M S Lima; Fernando Augusto Lavezzo Dias; Danilo Cândido de Almeida; Débora Tavares Resende E Silva; Ricardo Fernandez Perez; Rafael Luiz Pereira
Journal:  Mol Cell Biochem       Date:  2022-10-06       Impact factor: 3.842

3.  Crystal-induced collapsing podocytopathy and light chain proximal tubulopathy in monoclonal gammopathy of renal significance.

Authors:  George Terinte-Balcan; Gabriel Stefan; Simona Stancu; Suxia Wang; Mihaela Gherghiceanu
Journal:  J Nephrol       Date:  2022-06-10       Impact factor: 4.393

4.  Renal tubular gen e biomarkers identification based on immune infiltrates in focal segmental glomerulosclerosis.

Authors:  JunYuan Bai; XiaoWei Pu; YunXia Zhang; Enlai Dai
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

5.  Transition from minimal change disease to focal segmental glomerulosclerosis related to occupational exposure: A case report.

Authors:  Long Tang; Zhen Cai; Su-Xia Wang; Wen-Jing Zhao
Journal:  World J Clin Cases       Date:  2022-06-16       Impact factor: 1.534

Review 6.  Biomarkers in Primary Focal Segmental Glomerulosclerosis in Optimal Diagnostic-Therapeutic Strategy.

Authors:  Aleksandra Musiała; Piotr Donizy; Hanna Augustyniak-Bartosik; Katarzyna Jakuszko; Mirosław Banasik; Katarzyna Kościelska-Kasprzak; Magdalena Krajewska; Dorota Kamińska
Journal:  J Clin Med       Date:  2022-06-08       Impact factor: 4.964

Review 7.  Interventions for focal segmental glomerulosclerosis in adults.

Authors:  Elisabeth M Hodson; Aditi Sinha; Tess E Cooper
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

8.  Scanning ion conductance microscopy of live human glomerulus.

Authors:  Ruslan Bohovyk; Mykhailo Fedoriuk; Elena Isaeva; Andrew Shevchuk; Oleg Palygin; Alexander Staruschenko
Journal:  J Cell Mol Med       Date:  2021-03-21       Impact factor: 5.310

9.  Later Response to Corticosteroids in Adults With Primary Focal Segmental Glomerular Sclerosis Is Associated With Favorable Outcomes.

Authors:  Ilse M Rood; Aernoud Bavinck; Beata S Lipska-Ziętkiewicz; Dorien Lugtenberg; Franz Schaefer; Jeroen K J Deegens; Jack F M Wetzels
Journal:  Kidney Int Rep       Date:  2021-10-29

10.  A Retrospective Study of Clinical and Economic Burden of Focal Segmental Glomerulosclerosis (FSGS) in the United States.

Authors:  Kamyar Kalantar-Zadeh; Christine L Baker; J Brian Copley; Daniel I Levy; Stephen Berasi; Nihad Tamimi; Jose Alvir; Suneel M Udani
Journal:  Kidney Int Rep       Date:  2021-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.